Tanshinone IIA Inhibits miR-1 Expression through p38 MAPK Signal Pathway in Post-infarction Rat Cardiomyocytes
Authors:
- Yong ZhangYZYong Zhang
- Li ZhangLZLi Zhang
- Wenfeng ChuWCWenfeng Chu
- Bing WangBWBing Wang
- Jialin ZhangJZJialin Zhang
- Mei ZhaoMZMei Zhao
- Xuelian LiXLXuelian Li
- Baoxin LiBLBaoxin Li
- Yanjie LuYLYanjie Lu
- Baofeng YangBYBaofeng Yang
- Hongli ShanHSHongli Shan
Open Access
- 1 January 2010
- journal article
- research article
- Published by S. Karger AG in Cellular Physiology and Biochemistry
- Vol. 26 (6) , 991-998
Abstract
Tanshinone IIA is a fat-soluble pharmacologically active ingredient of Danshen, a well-known traditional Chinese medicine used for cardiovascular diseases such as coronary heart disease. Tanshinone IIA has been confirmed to suppress miR-1 and reduce the arrhythmogenesis after myocardial infarction (MI). However, the modulation mechanism is not clear. Tanshinone IIA was administrated daily for 7 days before ligation of the left anterior descending artery (LAD) and lasted for 3 months after LAD. Neonatal cardiomyocytes were exposed to 2% O2+95% N2 condition for 24 h to simulate ischemia in vivo. Protein expression was examined with Western blot and miR-1 level was quantified by Real-time PCR. Our results showed that tanshinone IIA relieved ischemia-induced injury by improving the cardiac function. This beneficial effect may due to the depression of the elevated miR-1 level in ischemic and hypoxic cardiomyocytes, which subsequently restored its target Cx43 protein. Furthermore, tanshinone IIA could inhibit activated p38 MAPK and heart special transcription factors SRF and MEF2, in ischemic and hypoxic cardiomyocytes. Pretreatment with p38 MAPK inhibitor, SB203580 (10 uM), significantly relieved hypoxia-induced miR-1 increment and restored its downstream target Cx43 protein expression. These data suggest that tanshinone IIA play a role in protection cardiomyocytes from ischemic and hypoxic injury. The effect is based on inhibiting miR-1 expression through p38 MAPK signal pathway. This might provide us a new target to explore the novel strategy for ischemic cardioprotection.Keywords
This publication has 30 references indexed in Scilit:
- Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA‐1British Journal of Pharmacology, 2009
- miR-1 Overexpression Enhances Ca 2+ Release and Promotes Cardiac Arrhythmogenesis by Targeting PP2A Regulatory Subunit B56α and Causing CaMKII-Dependent Hyperphosphorylation of RyR2Circulation Research, 2009
- Sodium Tanshinone IIA Sulfonate Protects Cardiomyocytes Against Oxidative Stress-mediated Apoptosis Through Inhibiting JNK ActivationJournal of Cardiovascular Pharmacology, 2008
- Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosisTranslational Research, 2008
- The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytesJournal of Cell Science, 2007
- The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2Nature Medicine, 2007
- Differential activation of mitogen-activated protein kinases in ischemic and nitroglycerin-induced preconditioningBasic Research in Cardiology, 2006
- Choline Produces Cytoprotective Effects Against Ischemic Myocardial Injuries: Evidence for the Role of Cardiac M3 Subtype Muscarinic Acetylcholine ReceptorsCellular Physiology and Biochemistry, 2005
- Antiischemic Effects of SB203580 Are Mediated Through the Inhibition of p38α Mitogen-Activated Protein KinaseCirculation Research, 2001
- The role of differential activation of p38‐mitogen‐activated protein kinase in preconditioned ventricular myocytesThe FASEB Journal, 2000